Hi Scotty, I think it may have been the clinical (not pre-clinical) data I was referring to that wasn't disclosed. It was stated in a webinar by Steven in context of the Phase 1a basket trial results, in which some sort of interesting activity had been observed in the other indications. The other indications included Myeloma, Gastric, Pancreatic and Colorectal cancers.
Whether its just a case of boosting the dosing level and/or adopting different dosing schedule, I don't know. However, it sounded like there might have been enough activity reported in some of the other indications to suggest a dosing level higher than 2,000 mg/m2 could garner efficacy in these too. Of course, further investigations will probably be way more complicated than just that. To gain meaningful efficacy in the solid tumour space, it's likely that combination strategies to enhance efficacy would also be the ultimate pursuit. But, that's not to be scoffed at! Our Phase 2 trial in CTCL could be the very catalyst to further studies in wider applications.
I had run some questions by Grok recently and, short of posting lengthy responses (which I find informative), here is a digestable summary covering this specific subject:-ConclusionPTX-100’s broad potential across 22% of cancers is plausible due to its unique GGT-1 inhibition targeting Rho, Rac, and Ral, offering a wider scope than G12C-specific inhibitors like sotorasib or adagrasib. Its early success in TCL (42% ORR) is promising, but unproven in solid tumors, where direct KRAS inhibitors and pan-RAS candidates like RMC-6236 have a head start. PTX-100’s success will hinge on demonstrating efficacy in major RAS-driven cancers, leveraging its favorable safety profile, and carving a niche in combination therapies or non-G12C indications. Ongoing Phase 2 trials and strategic partnerships will be critical to realizing its potential.
Add to My Watchlist
What is My Watchlist?
